The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
New Insights on Adenovirus as Vaccine Vectors
Open accessAbstract
Adenovirus (Ad) vectors were initially developed for treatment of genetic diseases. Their usefulness for permanent gene replacement was limited by their high immunogenicity, which resulted in rapid elimination of transduced cells through induction of T and B cells to antigens of Ad and the transgene product. The very trait that excluded their use for sustained treatment of genetic diseases made them highly attractive as vaccine carriers. Recently though results showed that Ad vectors based on common human serotypes, such as serotype 5, may not be ideal as vaccine carriers. A recently conducted phase 2b trial, termed STEP trial, with an AdHu5-based vaccine expressing antigens of human immunodeficiency virus 1 (HIV-1) not only showed lack of efficacy in spite of the vaccine's immunogenicity, but also suggested an increased trend for HIV acquisition in individuals that had circulating AdHu5 neutralizing antibodies prior to vaccination. Alternative serotypes from humans or nonhuman primates (NHPs), to which most humans lack pre-existing immunity, have been vectored and may circumvent the problems encountered with the use of AdHu5 vectors in humans. In summary, although Ad vectors have seen their share of setbacks in recent years, they remain viable tools for prevention or treatment of a multitude of diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Yang, Y., Li, Q., Ertl, H. C., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,032
Self-citationThe inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response
Muruve, D. A., Pétrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., Parks, R. J., & Tschopp, J. (2008) · Nature · doi:10.1038/nature06664 · Cited by 936
CD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 792
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Self-citationAdenovirus Serotype 5 Hexon Mediates Liver Gene Transfer
Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., Pink, R., Buckley, S. M. K., Greig, J. A., Denby, L., et al. (2008) · Cell · doi:10.1016/j.cell.2008.01.016 · Cited by 643
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
Yang, Y., Ertl, H. C. J., & Wilson, J. M. (1994) · Immunity · doi:10.1016/1074-7613(94)90074-4 · Cited by 611
Self-citationAbbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 491
Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J. M., Hehir, K. M., Keegan, J., Auger, C., Cramer, S. J., van Ormondt, H., van der Eb, A. J., et al. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.13-1909 · Cited by 479
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Liu, J., O’Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., et al. (2009) · Nature · doi:10.1038/nature07469 · Cited by 452
Raper, S. E., Yudkoff, M., Chirmule, N., Gao, G.-P., Nunes, F., Haskal, Z. J., Furth, E. E., Propert, K. J., Robinson, M. B., Magosin, S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712719 · Cited by 354
Adenovirus vectors for gene delivery
Benihoud, K., Yeh, P., & Perricaudet, M. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00007-5 · Cited by 350
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo
Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Hofherr, S. E., Barry, M. A., Stewart, P. L., & Shayakhmetov, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711757105 · Cited by 349
Prevalence and Quantitation of Species C Adenovirus DNA in Human Mucosal Lymphocytes
Garnett, C. T., Erdman, D., Xu, W., & Gooding, L. R. (2002) · Journal of Virology · doi:10.1128/jvi.76.21.10608-10616.2002 · Cited by 328
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
Shiver, J. W., & Emini, E. A. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104344 · Cited by 280
Zhang, Y., & Bergelson, J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.19.12125-12131.2005 · Cited by 258
A Replication-Defective Human Adenovirus Recombinant Serves as a Highly Efficacious Vaccine Carrier
XIANG, Z. Q., YANG, Y., WILSON, J. M., & ERTL, H. C. J. (1996) · Virology · doi:10.1006/viro.1996.0239 · Cited by 241
Self-citationRux, J. J., Kuser, P. R., & Burnett, R. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9553-9566.2003 · Cited by 233
Croyle, M. A., Chirmule, N., Zhang, Y., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4792-4801.2001 · Cited by 229
Tatsis, N., Fitzgerald, J. C., Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., Lin, S.-W., Bian, A., Xiang, Z. Q., Iparraguirre, A., et al. (2007) · Blood · doi:10.1182/blood-2007-02-062117 · Cited by 218
Self-citationA Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag
Fitzgerald, J. C., Gao, G.-P., Reyes-Sandoval, A., Pavlakis, G. N., Xiang, Z. Q., Wlazlo, A. P., Giles-Davis, W., Wilson, J. M., & Ertl, H. C. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1416 · Cited by 216
Self-citationHidaka, C., Milano, E., Leopold, P. L., Bergelson, J. M., Hackett, N. R., Finberg, R. W., Wickham, T. J., Kovesdi, I., Roelvink, P., & Crystal, R. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5309 · Cited by 216
Shayakhmetov, D. M., Li, Z.-Y., Ni, S., & Lieber, A. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5368-5381.2004 · Cited by 210
Appledorn, D. M., Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., Parameswaran, N., & Amalfitano, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2134 · Cited by 198
Development and optimization of an adenovirus production process
Kamen, A., & Henry, O. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.503 · Cited by 194
The influence of adenovirus fiber structure and function on vector development for gene therapy
Nicklin, S. A., Wu, E., Nemerow, G. R., & Baker, A. H. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.008 · Cited by 184
Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa
Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W. M., Kalish, M. L., & Ertl, H. C. J. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1210.060078 · Cited by 178
Self-citationSubversion of Host Defense Mechanisms by Adenoviruses
Burgert, H.-G., Ruzsics, Z., Obermeier, S., Hilgendorf, A., Windheim, M., & Elsing, A. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59421-2_16 · Cited by 157
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
Kostense, S., Koudstaal, W., Sprangers, M., Weverling, G. J., Penders, G., Helmus, N., Vogels, R., Bakker, M. E., Berkhout, B., Havenga, M. J. E., et al. (2004) · AIDS · doi:10.1097/00002030-200405210-00019 · Cited by 156
Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J. M., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A. A. C., Gillissen, G. F., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13207-13215.2004 · Cited by 148
Moraes, M. P., Santos, T. D. L., Koster, M. J., Turecek, T., Wang, H., Andreyev, V. G., & Grubman, M. J. (2007) · Journal of Virology · doi:10.1128/jvi.02775-06 · Cited by 147
Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy
Leen, A. M., Christin, A., Khalil, M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01689-07 · Cited by 141
Xiang, Z., Gao, G., Reyes‐Sandoval, A., Li, Y., Wilson, J. M., & Ertl, H. C. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10780-10789.2003 · Cited by 140
Self-citationThe adenovirus capsid: major progress in minor proteins
Vellinga, J., van der Heijdt, S., & Hoeben, R. C. (2005) · Journal of General Virology · doi:10.1099/vir.0.80877-0 · Cited by 140
Toietta, G., Mane, V. P., Norona, W. S., Finegold, M. J., Ng, P., McDonagh, A. F., Beaudet, A. L., & Lee, B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500930102 · Cited by 139
Liu, J., Ewald, B. A., Lynch, D. M., Denholtz, M., Abbink, P., Lemckert, A. A. C., Carville, A., Mansfield, K. G., Havenga, M. J. E., Goudsmit, J., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02616-07 · Cited by 132
Hidajat, R., Xiao, P., Zhou, Q., Venzon, D. J., Summers, L. E., Kalyanaraman, V. S., Montefiori, D. C., & Robert-Guroff, M. (2008) · Journal of Virology · doi:10.1128/jvi.01672-08 · Cited by 127
Raviprakash, K. S., Wang, D., Ewing, D. F., Holman, D. H., Block, K., Woraratanadharm, J., Chen, L., Hayes, C., Dong, J. Y., & Porter, K. R. (2008) · Journal of Virology · doi:10.1128/jvi.02724-07 · Cited by 126
Yeh, P., Dedieu, J.-F., Orsini, C., Vigne, E., Denèfle, P., & Perricaudet, M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.559-565.1996 · Cited by 125
Ertl, H. C. J., & Xiang, Z. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3579 · Cited by 122
Self-citationNunes, F. A., Furth, E. E., Wilson, J. M., & Raper, S. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950016852 · Cited by 121
Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma
Butterfield, L. H., Comin-Anduix, B., Vujanovic, L. N., Lee, Y., Dissette, V. B., Yang, J.-Q., Vu, H. T., Seja, E., Oseguera, D. K., Potter, D. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a8910 · Cited by 121
The Adenovirus Capsid Protein Hexon Contains a Highly Conserved Human CD4 + T-Cell Epitope
Olive, M., Eisenlohr, L. C., Flomenberg, N., Hsu, S. H., & Flomenberg, P. R. (2002) · Human Gene Therapy · doi:10.1089/104303402320138952 · Cited by 117
Pinto, A. R., Fitzgerald, J. C., Giles‐Davis, W., Gao, G. P., Wilson, J. M., & Ertl, H. C. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6774 · Cited by 113
Self-citationEffect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats
Nicol, C. G., Graham, D., Miller, W. H., White, S. J., Smith, T. A., Nicklin, S. A., Stevenson, S. C., & Baker, A. H. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.020 · Cited by 113
Viral Recombinant Vaccines to the E6 and E7 Antigens of HPV-16
He, Z., Wlazlo, A. P., Kowalczyk, D. W., Cheng, J., Xiang, Z., Giles‐Davis, W., & Ertl, H. C. J. (2000) · Virology · doi:10.1006/viro.2000.0271 · Cited by 109
Self-citationRux, J. J., & Burnett, R. M. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1167 · Cited by 106
Emerging roles and new functions of CD46
Liszewski, M. K., Kemper, C., Price, J. D., & Atkinson, J. P. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-005-0002-3 · Cited by 104
Magalhaes, I., Sizemore, D. R., Ahmed, R. K. S., Mueller, S., Wehlin, L., Scanga, C. A., Weichold, F., Schirru, G., Pau, M. G., Goudsmit, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003790 · Cited by 97
Immune Evasion by Adenovirus E3 Proteins: Exploitation of Intracellular Trafficking Pathways
Windheim, M., Hilgendorf, A., & Burgert, H.-G. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05599-1_2 · Cited by 96
Reyes‐Sandoval, A., Sridhar, S., Berthoud, T. K., Moore, A., Harty, J. T., Gilbert, S. C., Gao, G., Ertl, H. C. J., Wilson, J. M., & Hill, A. V. S. (2008) · European Journal of Immunology · doi:10.1002/eji.200737672 · Cited by 92
Self-citationHavenga, M. J. E., Vogels, R., Zuijdgeest, D., Radošević, K., Mueller, S., Sieuwerts, M., Weichold, F., Damen, I., Kaspers, J., Lemckert, A. A. C., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.81956-0 · Cited by 92
Okada, N., Saito, T., Masunaga, Y., Tsukada, Y., Nakagawa, S., Mizuguchi, H., Mori, K., Okada, Y., Fujita, T., Hayakawa, T., et al. (2001) · PubMed · Cited by 91
Philipson, L., & Pettersson, R. F. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05599-1_3 · Cited by 89
Nanda, A., Lynch, D. M., Goudsmit, J., Lemckert, A. A. C., Ewald, B. A., Sumida, S. M., Truitt, D. M., Abbink, P., Kishko, M., Gorgone, D. A., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14161-14168.2005 · Cited by 88
Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors
Yamaguchi, T., Kawabata, K., Koizumi, N., Sakurai, F., Kaneda‐Nakashima, K., Sakurai, H., Sasaki, T., Okada, N., Yamanishi, K., & Mizuguchi, H. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.016 · Cited by 87
Functions of the adenovirus E4 proteins and their impact on viral vectors
Weitzman, M. D. (2005) · Frontiers in bioscience · doi:10.2741/1604 · Cited by 85
Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses
Lasaro, M. O., Tatsis, N., Hensley, S. E., Whitbeck, J. C., Lin, S., Rux, J. J., Wherry, E. J., Cohen, G. H., Eisenberg, R. J., & Ertl, H. C. J. (2008) · Nature Medicine · doi:10.1038/nm1704 · Cited by 80
Self-citationLo, C.-Y., Wu, Z.-Q., Misplon, J. A., Price, G. E., Pappas, C., Kong, W., Tumpey, T. M., & Epstein, S. L. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.02.047 · Cited by 80
In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF
Bristol, J. A., Zhu, M., Ji, H. L., Mina, M., Xie, Y., Clarke, L., Forry‐Schaudies, S., & Ennist, D. L. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00103-5 · Cited by 76
Hensley, S. E., Giles‐Davis, W., McCoy, K. C., Weninger, W., & Ertl, H. C. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6032 · Cited by 73
Self-citationGilbert, R., Dudley, R. W. R., Liu, A.-B., Petrof, B. J., Nalbantoglu, J., & Karpati, G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg141 · Cited by 71
Koizumi, N., Kawabata, K., Sakurai, F., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.264 · Cited by 70
Host Immune Responses to Chronic Adenovirus Infections in Human and Nonhuman Primates
Calcedo, R., Vandenberghe, L. H., Roy, S., Somanathan, S., Wang, L., & Wilson, J. M. (2008) · Journal of Virology · doi:10.1128/jvi.02160-08 · Cited by 68
Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects
Seiler, M. P., Cerullo, V., & Lee, B. (2007) · Current Gene Therapy · doi:10.2174/156652307782151452 · Cited by 67
Andrews, J. L., Kadan, M. J., Gorziglia, M. I., Kaleko, M., & Connelly, S. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0264 · Cited by 66
Pichla-Gollon, S. L., Lin, S., Hensley, S. E., Lasaro, M. O., Haut, L. H., Drinker, M. S., Tatsis, N., Gao, G., Wilson, J. M., Ertl, H. C. J., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00405-09 · Cited by 66
Self-citationWorgall, S., Krause, A., Qiu, J., Joh, J., Hackett, N. R., & Crystal, R. G. (2007) · Journal of Virology · doi:10.1128/jvi.01246-07 · Cited by 62
Appaiahgari, M. B., Saini, M., Rauthan, M., Jyoti, J., & Vrati, S. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.05.023 · Cited by 61
Interaction of Systemically Delivered Adenovirus Vectors with Kupffer Cells in Mouse Liver
Smith, J. S., Xu, Z., Tian, J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.004 · Cited by 58
Zhou, D., Cun, A., Li, Y., Xiang, Z., & Ertl, H. C. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.027 · Cited by 57
Self-citationTatsis, N., Lin, S., Harris-McCoy, K., Garber, D. A., Feinberg, M. B., & Ertl, H. C. J. (2007) · Virology · doi:10.1016/j.virol.2007.05.028 · Cited by 57
Self-citationA Death in the Laboratory: The Politics of the Gelsinger Aftermath
Carmen, I. H. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0305 · Cited by 57
Innate Immune Response to Adenovirus
Nazir, S. A., & Metcalf, J. P. (2005) · Journal of Investigative Medicine · doi:10.2310/6650.2005.53605 · Cited by 56
Liu, X., Qiu, S.-B., Zou, W.-G., Pei, Z.-F., Gu, J.-F., Luo, C.-X., Ruan, H.-M., Chen, Y., Qi, Y.-P., & Qian, C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.003 · Cited by 54
A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines
Peruzzi, D., Dharmapuri, S., Cirillo, A., Bruni, B. E., Nicosia, A., Cortese, R., Colloca, S., Ciliberto, G., Monica, N. L., & Aurisicchio, L. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.12.051 · Cited by 54
Comparison of multiple vaccine vectors in a single heterologous prime-boost trial
Barefoot, B. E., Thornburg, N. J., Barouch, D. H., Yu, J.-S., Sample, C. J., Johnston, R. E., Liao, H. X., Kepler, T. B., Haynes, B. F., & Ramsburg, E. A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.007 · Cited by 53
Prasad, S. A., Norbury, C. C., Chen, W., Bennink, J. R., & Yewdell, J. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4809 · Cited by 53
Adenovirus Vector-Induced Immune Responses in Nonhuman Primates: Responses to Prime Boost Regimens
Tatsis, N., Lasaro, M. O., Lin, S., Xiang, Z., Zhou, D., DiMenna, L. J., Li, H., Bian, A., Abdulla, S., Li, Y., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900317 · Cited by 50
Self-citationShott, J. P., McGrath, S. M., Pau, M. G., Custers, J. H. H. V., Ophorst, O. J. A. E., Demoitié, M., Dubois, M., Komisar, J. L., Cobb, M., Kester, K. E., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.080 · Cited by 49
Luo, J., Xia, Q., Zhang, R., Lv, C., Zhang, W., Wang, Y., Cui, Q., Liu, L., Cai, R., & Qian, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4596 · Cited by 48
PHILLPOTTS, R. J., O’Brien, L. M., Appleton, R. E., Carr, S., & Bennett, A. M. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.06.056 · Cited by 47
Fattori, E., Zampaglione, I., Arcuri, M., Meola, A., Ercole, B. B., Cirillo, A., Folgori, A., Bett, A. J., Cappelletti, M., Sporeno, E., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302754 · Cited by 47
Onion, D., Crompton, L. J., Milligan, D. W., Moss, P. A. H., Lee, S. P., & Mautner, V. (2007) · Journal of General Virology · doi:10.1099/vir.0.82867-0 · Cited by 44
Zou, J., Yao, Z., Zhang, G., Wang, H., Xu, J., Yew, D. T., & Forster, E. L. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.05.003 · Cited by 39
Sekine, S., Kataoka, K., Fukuyama, Y., Adachi, Y., Davydova, J., Yamamoto, M., Kobayashi, R., Fujihashi, K., Suzuki, H., Curiel, D. T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8126 · Cited by 38
An adenoviral vector-based mucosal vaccine is effective in protection against botulism
Xu, Q., Pichichero, M. E., Simpson, L. L., Elias, M., Smith, L. A., & Zeng, M. (2009) · Gene Therapy · doi:10.1038/gt.2008.181 · Cited by 38
The Life and Times of Adenoviruses
Ginsberg, H. S. (1999) · Advances in virus research · doi:10.1016/s0065-3527(08)60363-2 · Cited by 36
Arévalo, M. T., Xu, Q., Paton, J. C., Hollingshead, S. K., Pichichero, M. E., Briles, D. E., Girgis, N., & Zeng, M. (2009) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2008.00518.x · Cited by 31
Control of Cellular and Viral Transcription During Adenovirus Infectio
Nevins, J. R. (1986) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238609082543 · Cited by 28
Wakayama, M., Abei, M., Kawashima, R., Seo, E., Fukuda, K., Ugai, H., Murata, T., Tanaka, N., Hyodo, I., Hamada, H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2103 · Cited by 25
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells
Marzio, G., Kerkvliet, E., Bogaards, J. A., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.12.011 · Cited by 12
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Metadata
- Authors
- Lasaro, M. O., & Ertl, H. C.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 17
- Issue
- 8
- Pages
- 1333-1339
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2030404196
- Cited by
- 263
- References
- 96
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.